Marc Perret

Senior Partner

Mr Perret joined Gilde in 2000 from Ciba/ Novartis. Prior to joining in October 2000, Mr. Perret gained operational and international experience during 17 years at the Novartis [Ciba] Group, in business development, restructuring, as country division head and ultimately as M&A Head of one of Novartis’ divisions.

His track record includes a $ 1 billion acquisition of a Merck & Co division, direct involvement in the multi-billion merger and listing of Switzerland-based Syngenta, and several smaller biotechnology deals.

Mr Perret was also responsible for the investment of Novartis/Syngenta in Gilde Healthcare I, during which time he built close relationships with Mr van der Meer and Mr de Graaf.

Mr Perret is an engineer from École Centrale de Lyon and received an M.B.A. from HEC Group / Stanford GSB.

He is a French national and speaks English, Italian and Spanish. Mr Perret led investments in Bioprotein, Conatus Pharmaceuticals, Innate Pharma and Neuro3D and represents Gilde on the board of Conatus. Former board representations include Bioprotein, CropDesign, Neuro3d and Innate Pharma.

Email perret@gilde.nl
Phone number +31 (0)30 2192527
vCard Download vCard
Marc Perret